Dynamics of interleukin-23/interleukin-17 axis and type 1 regulatory T cells across disease stages in axial spondyloarthritis.
Yeo J · 2026 · Clinical and experimental rheumatology
Reading the original? How to read a paper.
What this paper found
Comparing early, non-radiographic axial spondyloarthritis with established radiographic disease, people with early disease had more IL-23 in their blood and more IL-23-producing dendritic cells, while IL-17 levels were the same, and a calming cell type called Tr1 was lower early on. IL-23 may matter most at the start of the disease, which fits why IL-23 blockers disappointed in trials that mostly enrolled established disease.
Why this is on the map
Human data for the staged IL-23 model proposed in the GM-CSF review on the same thread.
On the map under this thread
DOI: 10.55563/clinexprheumatol/ijkhjz · opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
A disease-associated gene desert directs macrophage inflammation through ETS2
Nature
Identified a single 'switch' gene called ETS2, sitting on chromosome 21, that turns immune cells inflammatory across AS, IBD, and several other related diseases. Because no current drug targets ETS2, this points to a treatment direction beyond what's already available with TNF and IL-17 blockers.
Gut microbiota and ankylosing spondylitis: current insights and future challenges
Microbial Cell
Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.
Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients
Dove Medical Press
Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.